Evidence mapPaperPMID 41593458Full record

ArticleJournal of inflammation (London, England)2026

Sepsis induces long-term reprogramming of human HSPCs and drives myeloid dysregulation in sepsis survivors.

Marco De Zuani, Petra Lázničková, Marcela Hortová Kohoutková, Veronika Bosáková, Ivana Andrejčinová, Natália Vadovičová, Veronika Tomášková, Alexandra Mýtniková, Julie Štíchová, Tomáš Tomáš and 8 more

Abstract read
In one paragraph

Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marco De Zuani *International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Petra Lázničková *International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Marcela Hortová KohoutkováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Veronika BosákováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Ivana AndrejčinováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Natália VadovičováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Veronika TomáškováDepartment of Anaesthesiology and Intensive Care, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.
Alexandra MýtnikováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Julie ŠtíchováInstitute of Clinical Immunology and Allergology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.
Tomáš TomášFirst Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.
Jiří HrdýInstitute of Clinical Immunology and Allergology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 7, Prague, 12800, Czech Republic.
Kristýna BorákováNeonatology Department, Institute for the Care of Mother and Child, Podolske nabrezi 157/36, Prague, 14700, Czech Republic.
Stjepan UldrijanInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Marcela VlkováInstitute of Clinical Immunology and Allergology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.
Vladimír ŠrámekDepartment of Anaesthesiology and Intensive Care, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.
Martin HelánInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Kamila BendíčkováInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic.
Jan FričInternational Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno, 60200, Czech Republic. jan.fric@fnusa.cz.

Funding

DRO Institute of Hematology and Blood Transfusion - UHKT 00023736European Union's Horizon Europe research and innovation programme 101137484MEYS: Financed by European Union - Next Generation EU LX22NPO5107Ministry of Health of the Czech Republic in cooperation with the Czech Health Research Council NW25-06-00183
6 · The paper itself

Abstract

backgroundSepsis is a life-threatening condition characterised by an overwhelming immune response and high fatality. While most research has focused on its acute phase, many sepsis survivors remain immunologically weakened leaving them susceptible to serious complications from even mild infections. The mechanisms underlying this prolonged immune dysregulation remain unclear, limiting effective interventions. Here, we analysed whether sepsis induced long-term "training" in hematopoietic stem and progenitor cells (HSPCs), imprinting changes that persist in their myeloid progeny.

resultsPeripheral blood analysis of 8 sepsis survivors, 12 patients with septic shock, and 10 healthy donors revealed a significant expansion of CD38 + progenitors in survivors, with increased megakaryocyte-erythroid progenitors and a near significant reduction in mature neutrophil counts. This shift suggests impaired granulopoiesis, favouring immature, immunosuppressive granulocytes. Differentiated macrophages from survivors' HSPCs exhibited impaired metabolic pathways after lipopolysaccharide stimulation, with downregulation of tricarboxylic acid cycle and glycolysis genes, indicating altered immune metabolism. Pathway analysis revealed enhanced type-I interferon (IFN) and JAK-STAT signalling in survivors' macrophages, reflective of potentially tolerance-prone reprogramming. Finally, exposing healthy donor HSPCs to IFNβ during macrophage differentiation reduced HSPC proliferation, increased apoptosis, and induced a metabolic shift towards glycolysis over mitochondrial respiration.

conclusionsTogether, these findings suggest that sepsis induces lasting reprogramming in HSPCs leading to myeloid progeny with altered immune memory that might drive immune dysregulation in survivors. These data open avenues to explore potential targets to better manage long-term immune alterations in sepsis survivors.

Indexed as

DysregulationHematopoietic stem and progenitor cellMacrophageMetabolic impairmentReprogrammingSepsisSepsis survivorSeptic shockSignalling

Identifiers

PMID41593458
PMCPMC12903497

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.